Is Ketamine an Opioid? Drug Class, Effects, and Addiction Explained

No. Ketamine is not an opioid. It is a dissociative anaesthetic and non-competitive NMDA receptor antagonist that acts on the glutamate system, not the opioid system. Despite sharing some surface similarities with opioids — pain relief, sedation, and potential for dependence — ketamine works through an entirely different mechanism, and its effects are not reversed by naloxone, the standard opioid blocker. That single fact is the clearest clinical proof of the distinction.

This guide explains what drug class ketamine belongs to, how it differs from opioids, what its short- and long-term effects look like, and what treatment for ketamine dependence involves.

The Short Answer: Ketamine Is Not an Opioid

Opioids are a class of drugs that bind primarily to opioid receptors (mu, delta, and kappa) in the brain and body. They include heroin, morphine, fentanyl, and oxycodone. Opioids suppress the central nervous system, relieve pain, and slow breathing. An overdose can be fatal because of respiratory depression. Crucially, opioid effects are reversed by naloxone.

Ketamine does none of this through the opioid pathway. Its primary action is blocking the NMDA receptor, which is part of the glutamate neurotransmitter system. Although ketamine does have some affinity for opioid receptors, a peer-reviewed pharmacological review published in PMC6493357 confirms that “in humans, this analgesic effect is not antagonised by naloxone” — meaning naloxone cannot reverse ketamine’s effects the way it can reverse an opioid overdose. This confirms that ketamine’s clinical action is functionally independent of the opioid system.

The confusion between the two tends to arise because both can relieve pain, both can cause sedation, and both carry a risk of dependence. These shared features are the result of two drugs affecting the brain in different ways but producing some overlapping outcomes. The underlying mechanisms, the withdrawal profiles, and the medical management are distinct.

What Drug Class Does Ketamine Belong To?

Ketamine belongs to a class called dissociative anaesthetics, within the broader category of arylcycloalkylamines. Other dissociatives include phencyclidine (PCP) and nitrous oxide. The word “dissociative” refers to the way the drug separates sensory perception from conscious awareness: sensory signals reach the cortex but are not processed in the usual way, producing a detachment from the body and environment.

At a molecular level, ketamine is a non-competitive NMDA receptor antagonist. NMDA receptors are gated ion channels activated by glutamate, the brain’s primary excitatory neurotransmitter. Ketamine binds to a site inside the channel — known as the phencyclidine site — and reduces the time the channel stays open, blunting glutamate’s excitatory signals. This is the mechanism behind both its anaesthetic properties and its emerging use in treatment-resistant depression.

Ketamine’s medical uses are significant. It was synthesised in the 1960s as a safer alternative to PCP and has been used in hospitals worldwide as an anaesthetic, particularly in emergency medicine and paediatric settings, because it maintains airway reflexes and cardiovascular stability. More recently, esketamine (the S-enantiomer of ketamine) has been approved in the United States and Europe as a treatment for treatment-resistant depression, administered under medical supervision as a nasal spray.

Recreationally, ketamine is used for its dissociative and euphoric effects. In the UK, it is classified as a Class B drug under the Misuse of Drugs Act 1971, following reclassification from Class C in 2014. Possession carries a penalty of up to five years’ imprisonment; supply carries up to fourteen years.

Ketamine vs Opioids: Key Differences

The table below sets out the main clinical distinctions. Both substances can cause harm and dependence, but the nature of that harm differs in important ways.

The absence of an established medical substitute for ketamine dependence is clinically relevant. Unlike opioid dependence, where methadone or buprenorphine can stabilise a person and reduce craving during recovery, ketamine dependence is managed primarily through psychological treatment, abstinence support, and medical monitoring for organ harm.

What Are the Short-Term Effects of Ketamine?

At lower doses, ketamine produces a mild dissociative state: feelings of relaxation, detachment, and sometimes euphoria, alongside distorted perception of time and space. Users may feel detached from their surroundings or from their own body. Nausea is common.

At higher doses, the dissociation deepens into what is commonly called a “k-hole” — a state of profound disconnection in which the person may feel unable to move, communicate, or determine what is real. The experience can be distressing or, for some people who seek it recreationally, feel like an out-of-body or near-death experience. This state is not an overdose in the opioid sense, but it leaves the person vulnerable to injury or aspiration of vomit if they lose consciousness.

When snorted, ketamine typically takes effect within 15 to 20 minutes, with the main effects lasting 30 to 60 minutes. Injected ketamine acts much faster. The relatively short duration is one of the reasons repeated dosing in a session is common, which increases cumulative harm.

Can Ketamine Be Addictive?

Yes. Regular ketamine use can lead to dependence, though the nature of that dependence differs from opioids or alcohol.

Psychological dependence is the dominant pattern. People who use ketamine regularly often find themselves preoccupied with obtaining and using it, using more than they intended, and struggling to stop even when the consequences are evident. FRANK, the UK government drug information service, notes that regular use creates tolerance, meaning progressively higher doses are needed to achieve the same effect.

Ketamine rarely causes significant physical withdrawal symptoms such as tremors, vomiting, or seizures of the kind associated with alcohol or benzodiazepine withdrawal. However, psychological withdrawal can be severe. Users who stop after heavy, regular use often describe an overwhelming sense of anxiety and dread, low mood, and difficulty concentrating. These symptoms can last several days.

There is no established substitute medication for ketamine dependence. This is a meaningful difference from opioid dependence, where medications such as methadone and buprenorphine can stabilise a person during recovery and reduce the intensity of withdrawal. For ketamine, recovery relies primarily on psychological treatment: cognitive behavioural therapy (CBT), motivational approaches, group support, and, where co-occurring mental health conditions are present, psychiatric care.

According to the UK Advisory Council on the Misuse of Drugs (ACMD) 2026 review, treatment referrals for ketamine in the UK increased twelve-fold between 2015 and 2025, reflecting a significant and growing pattern of dependence.

If you are concerned about your own use or someone else’s, speaking to a GP or addiction specialist is the recommended first step.

Ketamine Bladder Syndrome: A Serious Long-Term Risk

Ketamine bladder, formally known as ketamine-induced uropathy, is one of the most serious and least discussed harms associated with regular ketamine use. It is not caused by infection. It results from ketamine and its metabolites being directly toxic to the urothelial cells lining the urinary tract.

Symptoms include: – A persistent, urgent need to urinate, sometimes every few minutes – Urinating only small volumes despite the urgency – Pain or burning when urinating – Blood in the urine (haematuria) – Bladder and lower abdominal pain – Incontinence

In severe cases, the bladder contracts into what is sometimes described as an “hourglass” shape, losing its normal capacity. At this stage, surgical repair or removal of the bladder may be necessary.

The ACMD 2026 review found that approximately 25% of regular ketamine users report at least one urinary symptom, with prevalence linked to dose and frequency of use. An NHS patient information resource on ketamine cystitis states that there is no cure for established ketamine-induced cystitis. Early cessation of use offers the best chance of halting and partially reversing the damage, but in advanced cases the damage is irreversible.

Even occasional ketamine use can trigger bladder problems in some people, and symptoms can appear sooner than users expect. Urinary symptoms linked to ketamine use should be assessed by a doctor as a priority, not managed at home or attributed to something else. If you are experiencing these symptoms alongside regular ketamine use, seek medical review promptly.

Other Long-Term Harms

Beyond the bladder, regular ketamine use is associated with several other long-term consequences.

Memory and cognitive function. Chronic use has been linked to impairment in working memory, concentration, and episodic memory. Flashbacks — intrusive re-experiences of dissociative states — can also occur in some people.

Mental health. Regular use is associated with depression and anxiety. Some heavy users develop psychotic symptoms, though whether ketamine causes psychosis directly or triggers it in people who are already vulnerable is an area where evidence is still developing. The cautious position is that if you have a personal or family history of psychosis, ketamine poses a meaningful psychiatric risk.

Liver and bile duct damage. Evidence of liver harm and biliary tract problems associated with heavy, long-term ketamine use is emerging in the clinical literature, though this is less established than the bladder evidence. Anyone with liver concerns should raise them with their GP.

Why Does Ketamine Sometimes Get Confused with Opioids?

The confusion is understandable. Ketamine relieves pain, produces sedation, can cause a loss of awareness, and carries a risk of dependence. All of these features are also associated with opioids. When people encounter ketamine described as an anaesthetic or a painkiller, it is natural to group it with opioids.

The similarity ends at the level of mechanism. Opioids work because they bind to opioid receptors and activate them. Ketamine works because it blocks NMDA glutamate receptors. The resulting states of sedation or pain relief are outcomes that can be produced by several different biological pathways — they are not a reliable guide to drug class.

A practical consequence of this distinction: if someone has taken ketamine and is unresponsive, giving naloxone will not help. This matters in an emergency. Naloxone is the correct first response to suspected opioid overdose. It has no meaningful effect on ketamine. Understanding the difference is not just a pharmacology point — it has real implications for how harm is managed.

Ketamine and opioids are sometimes used together, which compounds the risk of each. When they are co-ingested, the central nervous system effects may intensify unpredictably. This is an additional reason why any history of polydrug use should be disclosed to a treating clinician.

When to Seek Help for Ketamine Use

It can be difficult to recognise when recreational or experimental ketamine use has crossed into dependence. Some signs that use may have become problematic include:

• Needing to use more ketamine to feel the same effect
• Finding it difficult or impossible to go without it for a day or more
• Using it to cope with anxiety, boredom, or emotional distress rather than for recreation
• Spending increasing time obtaining, using, or recovering from its effects
• Continuing despite noticing physical or psychological problems

Bladder symptoms are a medical priority. If you are experiencing urinary urgency, pain, or blood in your urine alongside ketamine use, seek GP review promptly. Do not wait for symptoms to resolve on their own. Early intervention offers the best chance of preventing permanent damage.

For psychological dependence, speaking to a GP or an addiction specialist is the most effective first step. A professional assessment will help identify what support is appropriate, whether that is community-based treatment, a structured outpatient programme, or residential treatment abroad.

Ketamine Addiction Treatment at The Orchid Recovery, Chiang Mai

The Orchid Recovery is a boutique residential addiction and mental health treatment programme in the Hang Dong District of Chiang Mai, Thailand, providing personalised care for a maximum of 20 international clients at any one time. The centre provides specialised ketamine addiction treatment as part of its residential programme, working with international clients from the UK, Australia, and beyond.

Because ketamine dependence is primarily psychological, the residential environment is particularly suited to recovery. Geographic distance from familiar environments, social networks, and supply removes the daily triggers that sustain use. Intensive individual therapy — including CBT, DBT, and trauma-focused work where relevant — can address the drivers of dependence in a structured and supported setting. For clients with co-occurring mental health conditions such as anxiety, depression, or trauma, our dual-diagnosis approach means both conditions are addressed simultaneously rather than one after the other.

Medical oversight is provided by Dr. Suttipan Takkapaijit, our CEO and full-time on-site psychiatrist (MD, Thai medical licence 13333), with more than 30 years of experience in the addiction field. For any medical questions that arise during drug detox and early recovery, Dr. Suttipan’s on-site presence means the clinical picture is held in full.

Our residential programmes run across four, eight, or twelve weeks, with two months of complimentary aftercare included. For clients whose dependence on ketamine has been accompanied by other substance use, our programme can address co-occurring dependencies within the same residential stay. Details on what aftercare involves after leaving Chiang Mai are available on our website.

If someone you care about is using ketamine and showing signs of physical harm or psychological dependence, speaking to our admissions team is a confidential first step. We work with families and with individuals, and there is no pressure to commit to anything in an initial conversation.

Concerned about ketamine use? Speak to our admissions team in confidence Our small team in Chiang Mai works with international clients dealing with ketamine and drug dependence every week. We can talk you through what residential treatment involves, answer your questions, and help you decide what the right step looks like — with no pressure to commit. Get in touch: /contact-us/

Sources

1. Talk to FRANK (UK government drug information service). “Ketamine.” https://talktofrank.com/drug/ketamine
2. Advisory Council on the Misuse of Drugs (ACMD). “Ketamine: an updated review of use and harms.” January 2026. https://www.gov.uk/government/publications/ketamine-an-updated-review-of-use-and-harms/ketamine-an-updated-review-of-use-and-harms-accessible
3. NHS East Kent Hospitals. “Ketamine addiction, and ketamine bladder and induced cystitis.” https://leaflets.ekhuft.nhs.uk/ketamine-addiction-and-ketamine-bladder-and-induced-cystitis/html/
4. Zanos P et al. “Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings).” PMC6493357. https://pmc.ncbi.nlm.nih.gov/articles/PMC6493357/